Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.

Chen C, Gupta P, Parashar D, Nair GG, George J, Geethadevi A, Wang W, Tsaih SW, Bradley W, Ramchandran R, Rader JS, Chaluvally-Raghavan P, Pradeep S.

Oncogene. 2020 Feb 6. doi: 10.1038/s41388-020-1194-7. [Epub ahead of print]

PMID:
32029900
2.

miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.

Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P.

Cell Rep. 2019 Dec 24;29(13):4389-4406.e10. doi: 10.1016/j.celrep.2019.11.085.

3.

Identification and validation of a prognostic proteomic signature for cervical cancer.

Rader JS, Pan A, Corbin B, Iden M, Lu Y, Vellano CP, Akbani R, Mills GB, Simpson P.

Gynecol Oncol. 2019 Nov;155(2):324-330. doi: 10.1016/j.ygyno.2019.08.021. Epub 2019 Aug 30.

PMID:
31477280
4.

Preventive Effects by Black Raspberries of Endometrial Carcinoma Initiation and Promotion Induced by a High-Fat Diet.

Huang YW, Chen JH, Rader JS, Aguilera-Barrantes I, Wang LS.

Mol Nutr Food Res. 2019 Jun;63(12):e1900013. doi: 10.1002/mnfr.201900013. Epub 2019 Apr 12.

PMID:
30951235
5.

SOX11 hypermethylation as a tumor biomarker in endometrial cancer.

Shan T, Uyar DS, Wang LS, Mutch DG, Huang TH, Rader JS, Sheng X, Huang YW.

Biochimie. 2019 Jul;162:8-14. doi: 10.1016/j.biochi.2019.03.019. Epub 2019 Mar 29.

PMID:
30935961
6.

GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ.

Gynecol Oncol. 2019 May;153(2):335-342. doi: 10.1016/j.ygyno.2019.02.028. Epub 2019 Feb 28.

7.

Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer.

Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH.

Int J Gynecol Cancer. 2019 Jan;29(1):53-59. doi: 10.1136/ijgc-2018-000008.

PMID:
30640684
8.

Genetic variations in human papillomavirus and cervical cancer outcomes.

Rader JS, Tsaih SW, Fullin D, Murray MW, Iden M, Zimmermann MT, Flister MJ.

Int J Cancer. 2019 May 1;144(9):2206-2214. doi: 10.1002/ijc.32038. Epub 2019 Jan 4.

PMID:
30515767
9.

HLA and KIR Associations of Cervical Neoplasia.

Bao X, Hanson AL, Madeleine MM, Wang SS, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Garland SM, Tabrizi SN, Wentzensen N, Sitas F, Trimble C, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA, Duncan EL, Sun YP, Leo PJ.

J Infect Dis. 2018 Nov 5;218(12):2006-2015. doi: 10.1093/infdis/jiy483.

10.

miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation.

Zhang W, Chen JH, Shan T, Aguilera-Barrantes I, Wang LS, Huang TH, Rader JS, Sheng X, Huang YW.

Lab Invest. 2018 Nov;98(11):1397-1407. doi: 10.1038/s41374-018-0092-x. Epub 2018 Jun 28.

11.

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R.

Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2.

12.

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C.

Cell Rep. 2018 Apr 3;23(1):194-212.e6. doi: 10.1016/j.celrep.2018.03.063.

13.

Correction: Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study.

Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Hallmans G, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Trimble CL, Garland S, Tabrizi SN, Wentzensen N, Sitas F, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA.

PLoS Genet. 2018 Mar 1;14(3):e1007257. doi: 10.1371/journal.pgen.1007257. eCollection 2018 Mar.

14.

Correction: Identification of a serum-induced transcriptional signature associated with metastatic cervical cancer.

Palatnik A, Ye S, Kendziorski C, Iden M, Zigman JS, Hessner MJ, Rader JS.

PLoS One. 2018 Feb 23;13(2):e0193687. doi: 10.1371/journal.pone.0193687. eCollection 2018.

15.

Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen.

Spurgeon ME, den Boon JA, Horswill M, Barthakur S, Forouzan O, Rader JS, Beebe DJ, Roopra A, Ahlquist P, Lambert PF.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9076-E9085. doi: 10.1073/pnas.1712018114. Epub 2017 Oct 9.

16.

IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients.

Choi J, Ye S, Eng KH, Korthauer K, Bradley WH, Rader JS, Kendziorski C.

Stat Biosci. 2017 Jun;9(1):1-12. doi: 10.1007/s12561-016-9144-1. Epub 2016 Mar 29.

17.

Identification of a serum-induced transcriptional signature associated with metastatic cervical cancer.

Palatnik A, Ye S, Kendziorski C, Iden M, Zigman JS, Hessner MJ, Rader JS.

PLoS One. 2017 Aug 30;12(8):e0181242. doi: 10.1371/journal.pone.0181242. eCollection 2017. Erratum in: PLoS One. 2018 Feb 23;13(2):e0193687.

18.

Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study.

Leo PJ, Madeleine MM, Wang S, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Hallmans G, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Trimble CL, Garland S, Tabrizi SN, Wentzensen N, Sitas F, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA.

PLoS Genet. 2017 Aug 14;13(8):e1006866. doi: 10.1371/journal.pgen.1006866. eCollection 2017 Aug. Erratum in: PLoS Genet. 2018 Mar 1;14 (3):e1007257.

19.

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D.

Gynecol Oncol. 2017 May;145(2):291-297. doi: 10.1016/j.ygyno.2017.02.040. Epub 2017 Mar 10.

20.

Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression.

Liu P, Iden M, Fye S, Huang YW, Hopp E, Chu C, Lu Y, Rader JS.

Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):642-650. doi: 10.1158/1055-9965.EPI-16-0368. Epub 2017 Jan 9.

21.

Divergent viral presentation among human tumors and adjacent normal tissues.

Cao S, Wendl MC, Wyczalkowski MA, Wylie K, Ye K, Jayasinghe R, Xie M, Wu S, Niu B, Grubb R 3rd, Johnson KJ, Gay H, Chen K, Rader JS, Dipersio JF, Chen F, Ding L.

Sci Rep. 2016 Jun 24;6:28294. doi: 10.1038/srep28294.

22.

The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis.

Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS.

PLoS One. 2016 May 27;11(5):e0156274. doi: 10.1371/journal.pone.0156274. eCollection 2016.

23.

Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain.

Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, Mutch DG, Rader JS, Thaker PH.

Gynecol Oncol. 2016 Jul;142(1):76-82. doi: 10.1016/j.ygyno.2016.04.030. Epub 2016 May 8.

24.

Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma.

Bradley WH, Eng K, Le M, Mackinnon AC, Kendziorski C, Rader JS.

BMC Clin Pathol. 2015 Sep 24;15:17. doi: 10.1186/s12907-015-0017-1. eCollection 2015.

25.

Polymorphisms in immune mediators associate with risk of cervical cancer.

Zhang Z, Fye S, Borecki IB, Rader JS.

Gynecol Oncol. 2014 Oct;135(1):69-73. doi: 10.1016/j.ygyno.2014.07.106. Epub 2014 Aug 12.

26.

Hypermethylation of miR-203 in endometrial carcinomas.

Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS.

Gynecol Oncol. 2014 May;133(2):340-5. doi: 10.1016/j.ygyno.2014.02.009. Epub 2014 Feb 14.

27.

Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer.

Ma D, Hovey RL, Zhang Z, Fye S, Huettner PC, Borecki IB, Rader JS.

Gynecol Oncol. 2013 Nov;131(2):445-50. doi: 10.1016/j.ygyno.2013.07.113. Epub 2013 Aug 6.

28.

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS.

Gynecol Oncol. 2013 Jul;130(1):64-8. doi: 10.1016/j.ygyno.2013.04.009. Epub 2013 Apr 13.

29.

Pathway index models for construction of patient-specific risk profiles.

Eng KH, Wang S, Bradley WH, Rader JS, Kendziorski C.

Stat Med. 2013 Apr 30;32(9):1524-35. doi: 10.1002/sim.5641. Epub 2012 Oct 16.

30.

Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer.

Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, Rogers BE, Yang Q, Watson M, Rader JS, Grigsby PW.

Clin Cancer Res. 2012 Mar 1;18(5):1464-71. doi: 10.1158/1078-0432.CCR-11-2485. Epub 2012 Jan 10.

31.

Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer.

Hagemann AR, Zighelboim I, Odibo AO, Rader JS, Mutch DG, Powell MA.

Breast J. 2011 Jan-Feb;17(1):103-5. doi: 10.1111/j.1524-4741.2010.01017.x. Epub 2010 Dec 14. No abstract available.

PMID:
21155918
32.

The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy.

Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, Mutch DG, Grigsby PW.

Cancer. 2011 Mar 1;117(5):948-56. doi: 10.1002/cncr.25544. Epub 2010 Oct 13.

33.

HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer.

Martin MP, Borecki IB, Zhang Z, Nguyen L, Ma D, Gao X, Qi Y, Carrington M, Rader JS.

Immunogenetics. 2010 Dec;62(11-12):761-5. doi: 10.1007/s00251-010-0477-5. Epub 2010 Sep 21.

34.

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37. doi: 10.1007/s00280-010-1410-1. Epub 2010 Aug 8.

35.

Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.

Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, Grigsby PW.

J Clin Oncol. 2010 Apr 20;28(12):2108-13. doi: 10.1200/JCO.2009.25.4151. Epub 2010 Mar 22.

PMID:
20308664
36.

TP53, MDM2, NQO1, and susceptibility to cervical cancer.

Hu X, Zhang Z, Ma D, Huettner PC, Massad LS, Nguyen L, Borecki I, Rader JS.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):755-61. doi: 10.1158/1055-9965.EPI-09-0886. Epub 2010 Mar 3.

37.

A microRNA expression signature for cervical cancer prognosis.

Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X.

Cancer Res. 2010 Feb 15;70(4):1441-8. doi: 10.1158/0008-5472.CAN-09-3289. Epub 2010 Feb 2.

38.

"Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer.

Zighelboim I, Kizer N, Taylor NP, Case AS, Gao F, Thaker PH, Rader JS, Massad LS, Mutch DG, Powell MA.

Gynecol Oncol. 2010 Mar;116(3):370-3. doi: 10.1016/j.ygyno.2009.11.031. Epub 2009 Dec 16.

PMID:
20015540
39.

Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer.

Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, Grigsby P, Allsworth JE, Rader JS.

Gynecol Oncol. 2010 Mar;116(3):539-43. doi: 10.1016/j.ygyno.2009.09.037. Epub 2009 Nov 10.

40.

Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.

Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS.

Gynecol Oncol. 2010 Mar;116(3):438-41. doi: 10.1016/j.ygyno.2009.09.045. Epub 2009 Nov 5. Erratum in: Gynecol Oncol. 2010 Jul;118(1):99.

PMID:
19896180
41.

Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.

Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, Powell MA, Grigsby PW.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1085-91. doi: 10.1016/j.ijrobp.2009.06.041. Epub 2009 Oct 31.

PMID:
19880262
42.

The value of perioperative imaging in patients with uterine sarcomas.

Nugent EK, Zighelboim I, Case AS, Gao F, Thaker PH, Rader JS, Mutch DG, Massad LS.

Gynecol Oncol. 2009 Oct;115(1):37-40. doi: 10.1016/j.ygyno.2009.06.013. Epub 2009 Jul 4.

43.

Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake.

Kidd EA, Spencer CR, Huettner PC, Siegel BA, Dehdashti F, Rader JS, Grigsby PW.

Cancer. 2009 Aug 1;115(15):3548-54. doi: 10.1002/cncr.24400.

44.

ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.

Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ.

J Clin Oncol. 2009 Jul 1;27(19):3091-6. doi: 10.1200/JCO.2008.19.9802. Epub 2009 May 26. Erratum in: J Clin Oncol. 2009 Oct 1;27(28):4819.

45.

CD83 polymorphisms and cervical cancer risk.

Yu KJ, Rader JS, Borecki I, Zhang Z, Hildesheim A.

Gynecol Oncol. 2009 Aug;114(2):319-22. doi: 10.1016/j.ygyno.2009.04.033. Epub 2009 May 15.

46.

Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.

Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL.

Gynecol Oncol. 2009 Jul;114(1):75-9. doi: 10.1016/j.ygyno.2009.03.036. Epub 2009 May 1.

PMID:
19410279
47.

Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer.

Kizer N, Zighelboim I, Rader JS.

Int J Gynecol Cancer. 2009 Feb;19(2):237-8. doi: 10.1111/IGC.0b013e31819c54db.

PMID:
19395999
48.

Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6.

Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM.

RNA. 2009 Apr;15(4):637-47. doi: 10.1261/rna.1442309. Epub 2009 Mar 3.

49.

Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation.

Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS.

Gynecol Oncol. 2009 Mar;112(3):553-7. doi: 10.1016/j.ygyno.2008.11.026. Epub 2009 Jan 9.

PMID:
19135232
50.

A unified sample preparation protocol for proteomic and genomic profiling of cervical swabs to identify biomarkers for cervical cancer screening.

Rader JS, Malone JP, Gross J, Gilmore P, Brooks RA, Nguyen L, Crimmins DL, Feng S, Wright JD, Taylor N, Zighelboim I, Funk MC, Huettner PC, Ladenson JH, Gius D, Townsend RR.

Proteomics Clin Appl. 2008 Dec;2(12):1658-69. doi: 10.1002/prca.200780146. Epub 2008 Oct 22.

Supplemental Content

Loading ...
Support Center